Background In the presence of ischaemia, albumin undergoes changes resulting in the formation of ischaemia-modified albumin (IMA). Increased serum concentrations of IMA have been found in patients with myocardial ischaemia. The purpose of this study was threefold: to evaluate the albumin cobalt binding (ACB) assay for measurement of IMA on the Beckman Coulter LX-20; to establish a reference range for IMA; and to investigate the relationship between IMA and total albumin concentrations.
Introduction
Di¡erentiating myocardial ischaemia from non-cardiac causes of chest pain remains a diagnostic challenge. 1 In the emergency department, the diagnosis of acute myocardial infarction is made on electrocardiographic (ECG) recordings and on abnormalities of biochemical markers such as cardiac troponin and creatine kinase concentrations. 2 However, these may be normal in the presence of critical coronary artery disease causing myocardial ischaemia but not infarction. It is estimated that in the UK approximately 6% of patients presenting with chest pain who have myocardial damage are dis-charged, while the majority of patients admitted for investigation of chest pain do not have acute coronary syndrome (ACS). 3 Figures from the USA re£ect a similar picture, 4 resulting in great cost to both the patient and the health services.
A sensitive and speci¢c test that identi¢es myocardial ischaemia has the potential to impact positively on patient care by detecting myocardial ischaemia before infarction occurs, allowing for safer and more e¡ective patient management. A new biomarker, namely ischaemia-modi¢ed albumin (IMA), has been claimed to be increased in patients with myocardial ischaemia. 5--9 In the presence of ischaemia, the amino terminal end of the albumin molecule undergoes structural modi¢cations resulting in a reduction in its ability to bind metals such as cobalt. 10 These structural changes are thought to occur as a result of acidosis and/or free radical damage. 11, 12 IMA is the ¢rst biomarker for myocardial ischaemia to be approved by the Food and Drug Administration for use in ruling out ACS when used in conjunction with troponin and ECG testing. 13 Currently, IMA is measured indirectly by determining the cobalt-binding capacity of albumin in serum samples. In the assay, marketed as the albumin cobalt binding (ACB) test, cobalt is incubated with the patient's serum and any unbound cobalt is then subsequently detected by a coupled colorimetric reaction. IMA has a reduced capacity for binding cobalt, thus leaving more unbound cobalt to react in the assay. Studies carried out by the manufacturer of the ACB assay have shown that cobalt binding by serum is speci¢c to human serum albumin, and that the amount of cobalt bound is proportional to the total serum albumin concentration. 14 In this paper, we report on the analytical performance of the ACB assay on the Beckman Coulter LX-20 platform. As part of the study, we established a reference range for IMA in the population served by our laboratory. Since the amount of cobalt available for reaction in the ACB assay is dependent on both the total serum albumin and IMA concentrations, we also present data on the relationship between these entities in our reference population.
Materials and methods
Serum IMA concentrations were measured with the ACB assay (Inverness Medical Innovations, Inc, Massachusetts, USA, formerly supplied by Ischemia Technologies) on the Beckman Coulter LX-20 platform (Beckman Coulter, California, USA) according to the manufacturer's instructions. Cobalt chloride was incubated with the sample, and unbound cobalt was then reacted with dithiothreitol (DTT) to form a coloured product, which was measured bichromatically (primary wavelength 470 nm; secondary wavelength 700 nm). IMA had a reduced capacity for binding cobalt, thus leaving more unbound cobalt to react with DTT.
Total serum albumin concentrations were analysed on the Beckman Coulter LX-20 using the manufacturer's reagent, bromocresol purple (BCP).
Comparison with a reference method was part of the manufacturer's installation protocol to verify that the ACB assay was performing according to speci¢cation on the LX-20 in our laboratory. Two aliquots were prepared from each of 20 serum samples by the manufacturer. One aliquot was assayed on the Cobas Mira Plus (ABX Diagnostics Ltd, London, UK) by the manufacturer and the second aliquot was assayed in duplicate on the LX-20 in our laboratory. Prior to analysis, samples were stored frozen at À201C by the manufacturer and were received frozen by our laboratory. Analysis of IMA was completed within 1h of thawing.
Within-batch and between-batch imprecisions were evaluated using fresh sera and quality control material supplied by the manufacturer, respectively. Betweenbatch imprecision was assessed over 22 runs on 17 di¡erent days using sample duplicate analysis, and involved the use of eight reagent kits consisting of two di¡erent lot numbers.
The stability of IMA in frozen samples was assessed using paired aliquots of serum samples (n ¼10). One of the aliquots was frozen within 1h of collection and stored at À201C for periods between one day and six weeks before analysis, and the other aliquot was analysed fresh within 2.5 h of collection. Twelve aliquots of one serum sample were stored at À201C with the aliquots (each one only once) being thawed and analysed at intervals over a four-month period. All samples stored at À201C were analysed within 1h of removal from the freezer. To assess stability at 41C, samples (n ¼ 5) were analysed following storage at that temperature for periods of between 5 and 24 h.
A reference range was established using non-fasting serum samples obtained from a population of 81 healthy volunteers (28 men, age range 22--86 years; median, 44 years; 53 women, age range 22--86 years; median, 42 years). Full ethical approval and informed consent was obtained before sampling. None of the subjects were pregnant or had any prior history of heart disease. None were taking any antihypertensive or lipid-lowering medication, and none were su¡ering from any chronic disease, including diabetes, renal or liver disease. Samples were collected into plain tubes between 9 am and 5 pm, and serum was frozen within 1.5 h of blood draw and stored at À201C for between ¢ve to six weeks before analysis. Samples were analysed within 1h of removal from the freezer.
Statistical analyses were performed using ' Analyse-It' software for Microsoft Excel (Analyse-It Software Ltd, Leeds, UK).
Results Imprecision
Within-batch coe⁄cient of variation (CV), n ¼ 20, derived from fresh patient serum samples with mean IMA concentrations of 88, 99 and 120 KU/L were 1.4, 2.0 and 2.5%, respectively. Between-batch CVs on quality control material with mean IMA concentrations of 74 KU/L (n ¼ 41), 84 KU/L (n ¼ 46) and 123 KU/L (n ¼ 47) were 3.4, 3.3 and 3.0%, respectively. The average between-batch CV for total serum albumin analysis on the LX-20 was 3.0%. The combined analytical imprecision (CV) of IMA and total serum albumin measurement was calculated to be 4.4%.
Stability of IMA
IMA concentrations increased in serum samples by an average of 10% (range 7.6--13.6%) when stored at 41C for 5 to 24 h (n ¼ 5). Storage at À201C resulted in an average increase of 7% (range 2.4--11.7%) in IMA concentrations when compared to that measured in the corresponding fresh serum sample (n ¼10). However, once frozen and stored at À201C, IMA concentrations were stable for four months; the imprecision (CV) obtained on frozen aliquots of a serum sample was 4.3% (12 analyses in total).
Comparison with reference method
Serum samples, previously analysed on a reference instrument (Cobas Mira Plus, reference instrument data supplied by the manufacturer), were analysed for IMA on the Beckman Coulter LX-20. Bland--Altman analysis (Figure 1) showed the LX-20 to have an overall negative bias (mean; 7 KU/L) compared with the Mira Plus and that the bias increased with increases in concentration. Comparison of the two sets of data using the Passing and Bablok method conversion yielded the following equation: y (LX-20) ¼ 0.8662 (Mira Plus) þ 10.945 ( Figure 2 ) with a Pearson correlation coe⁄cient (r) of1. The ACB manufacturer considered the slope and intercept obtained to be consistent with expected performance on an LX-20.
Reference range
The IMA concentrations found in our reference population (n ¼ 81) ranged from 82.0 to 110.1 KU/L (median, 100.1 KU/L) ( Figure 3 ). The 2.5th and 97.5th percentiles were 85.6 and 110.0 KU/L, respectively. The upper cut-o¡ level of 110 KU/L (97.5th percentile) is considerably higher than the 85 KU/L cut-o¡ speci¢ed by the manufacturer. There was no di¡erence seen between IMA concentrations in male (median, 99.1 KU/L) and female (median, 100.7 KU/L) subjects (P ¼ 0.12, Mann--Whitney test). Comparison of age and IMA concentrations showed a weak positive correlation (Pearson correlation coe⁄cient of r ¼ 0.31, Po0.05). However, comparing IMA concentrations of the population below the median age of 44 years (median, 98.7 KU/L) and above (median, 101.2 KU/L) showed no signi¢cant di¡erence (P ¼ 0.053, Mann--Whitney test). Comparison of IMA concentrations of the population below the age of 60 years (range of results, --82.0--109.8 KU/L; median, 98.8 KU/L.) and above the age of 60 years (range of results, --90.8--110.1 KU/L; median, 103.8 KU/L) did show a small, but signi¢cant, di¡erence (P ¼ 0.0085, Mann--Whitney test).
Effect of total serum albumin concentrations
There was a signi¢cant inverse relationship found between total serum albumin and IMA concentrations in our healthy reference population (r ¼ À0.66, Po0.0001) ( Figure 4 ). None of the reference population subjects with an albumin o44 g/L had an IMA o94 KU/L. Similarly, none of the subjects with an albumin 446 g/L had an IMA result 4102 KU/L. Referring to the equation obtained by the Passing and Bablok method conversion (y(IMA) ¼ À2.185 Â (Albumin) þ 196.63), it was determined that for every 1g/L increase in albumin, IMA concentrations fell by 2.185 KU/L and vice versa. Using the median concentration of albumin (44 g/L) obtained in our reference population as a reference point, we devised a formula to correct IMA for total serum albumin concentrations --corrected IMA (KU/L) ¼ measured IMA (KU/L)--[(44Àalbumin (g/ L)) Â 2]. For convenience, 2.185 was rounded to 2 for use in the formula. This formula is analogous to that devised to calculate 'adjusted' calcium concentrations from total serum calcium and albumin concentrations. The corrected IMA (cIMA) concentrations (using above formula) in our reference population ranged from 86.1 to 111.7 KU/L (median, 100.0 KU/L) with the 2.5th and 97.5th percentiles being 91 and 110 KU/L, respectively ( Figure 5 ).
Discussion
Clinicians, in particular those in emergency departments, await the ideal biomarker to detect myocardial ischaemia before myocyte necrosis occurs. At present, it appears that the FDA approved IMA test is the most promising. 1, 8, 15 Several studies have shown that IMA is an early marker of myocardial ischaemia in the setting of percutaneous coronary intervention (PCI). 5,16--18 Other studies have looked at serum IMA concentrations in patients presenting to emergency departments with symptoms of ACS, and have found that IMA has high sensitivity but poor speci¢city for the detection of myocardial ischaemia, with a resulting high negative predictive value. 6,7,19--22 Increases in IMA concentrations have also been reported in conditions not associated with myocardial ischaemia such as skeletal muscle ischaemia, gastrointestinal ischaemia, stroke, end stage renal disease and some neoplasms. 9,23--27 The ACB test is currently available only on Roche instrumentation 28 (Roche Modular P and 911 and Cobas Mira Plus) and the Beckman Coulter LX-20. As far as we are aware, this is the ¢rst published independent evaluation of the ACB assay on the Beckman Coulter LX-20. We found the assay to perform satisfactorily on the Beckman Coulter LX-20 with acceptable imprecision (between batch CVs o3.5%) and reliability in that no run was rejected due to unacceptable performance. However, the instability of IMA in serum samples may impact on its routine use, since samples have to be analysed within 2.5 h of blood draw or otherwise have to be stored frozen until analysis. We con¢rmed this instability by ¢nding that IMA concentrations increased in serum by an average of 10% when stored at 41C for periods longer than recommended.
The 97.5th percentile value (110 KU/L) for IMA concentrations that we established in our reference population is considerably higher than the cut-o¡ level of 85 KU/L speci¢ed by the manufacturer (data that were obtained using the Cobas Mira Plus). 14 One possible explanation for the di¡erence seen is that our reference population di¡ered in their IMA concentrations from that tested by the manufacturer. However, it is interesting to note that Zapico-Muniz et al., 29 using the Cobas Mira, found the 95th percentile level of IMA in their reference population to be 101 KU/L, which is closer to our cut-o¡ level than that of the manufacturer. Furthermore, various researchers who have looked at IMA concentrations in ACS feel there is a grey area between 85 and 105 KU/L, and that more studies are needed to determine the signi¢cance of concentrations in this range. 20, 30, 31 We observed no gender di¡erence in IMA concentrations and a weak positive correlation of IMA with age, with a small but signi¢cant di¡erence in IMA values in individuals less than 60 years of age, compared with those above this age. However, we do not consider this di¡erence su⁄cient to warrant agerelated reference ranges, as the upper values of the IMA concentrations obtained in both age groups were similar.
The signi¢cant inverse relationship found between total serum albumin concentrations and IMA concentrations in our study con¢rms the ¢ndings of previous studies. 29, 32 Indeed, the inverse relationship found in our study is remarkably similar to that estimated previously: IMA ¼ À2.36 (albumin) þ 200 32 and IMA ¼ À2.366 (albumin) þ 186.4. 29 In one of the above studies, IMA concentrations were estimated in patients undergoing exercise myocardial perfusion scintigraphy, and it was found that IMA measurements re£ected serum albumin concentrations, but not myocardial ischaemia. 32 In the present paper, we propose a method for the correction of measured IMA concentrations, taking into account the inverse relationship with total serum albumin concentrations observed in our reference population. The basis of the correction is analogous to that used widely for the adjustment of total serum calcium concentrations, taking into account total serum albumin concentrations, in order to assess the ionized calcium status of the patient. 33 The similarity between the reference range obtained for cIMA and measured IMA in our healthy population is not surprising considering that the applied correction for total serum albumin results in an increase in IMA values in some individuals and a decrease in others. Since the combined analytical imprecision of IMA and total albumin measurement (4.4%) is small compared with the extremes of adjustments made to IMA concentrations (À12.8 to 15.7%) in individual subjects, it is unlikely to account solely for these changes.When applied to a patient population, the proposed correction will potentially have more impact on IMA concentrations since total albumin concentrations are generally lower than in an ambulatory reference population and, if left uncorrected, could result in falsely elevated concentrations of IMA being estimated.
In summary, the ACB assay for measuring serum IMA concentrations had a very satisfactory analytical performance on the Beckman Coulter LX-20. However, the need to process specimens quickly due to the instability of IMA, may impact on its routine use. Furthermore, it may prove necessary to correct IMA concentrations for the level of total serum albumin present to obtain a clearer picture of the signi¢cance of IMA concentrations in patients with ACS. We believe that the method of correcting measured IMA values for total albumin concentrations proposed in this paper will be helpful. Some issues remain about the ACB assay itself; the exact nature of the entity or entities the assay is measuring is not known and the fact that the calibrant supplied with the kit is a chelating agent (ethylenediaminetetraacetic acid (EDTA)) rather than a known concentration of IMA. Even with these uncertainties, the measurement of IMA by the ACB assay may have a role in the evaluation of patients with ACS, but not before further studies are carried out to fully assess whether IMA is indeed a useful marker of myocardial ischaemia.
